Goldman Sachs Maintains Neutral on Edgewise Therapeutics, Raises Price Target to $36
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Goldman Sachs analyst Paul Choi maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Neutral and raises the price target from $32 to $36.
Goldman Sachs analyst Paul Choi maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Neutral and raises the price target from $32 to $36.